Getein Biotech Inc., (SHA: 603387), a company based in China with a focus on in vitro diagnostic (IVD) solutions, has entered into a strategic partnership with Dymind Biotechnology Co., Ltd. Both firms are dedicated to the IVD sector, and this collaboration aims to enhance resource sharing and capitalize on their respective strengths to foster technical innovation and expand market presence within the industry. The financial terms of the agreement have not been disclosed.
Getein Biotech has been making significant strides in the fields of point-of-care testing (POCT) and chemiluminescence, offering a range of diagnostic products that cater to immediate patient care needs. Dymind Biotechnology, on the other hand, has established expertise in blood cell analysis, a critical component of clinical diagnostics. The synergy between the two companies is expected to lead to advancements in IVD technology and improved diagnostic solutions for patients.- Flcube.com
